Upgrade to SI Premium - Free Trial

Teva Pharmaceutical (TEVA) Tops Q4 EPS by 2c; Reaffirms Outlook

February 6, 2014 7:03 AM
Teva Pharmaceutical (NYSE: TEVA) reported Q4 EPS of $1.42, $0.16 better than the analyst estimate of $1.40. Revenue for the ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Categories

Earnings FDA Hot Corp. News Hot Earnings Hot List